MX2013007938A - Novel bicyclic compound or salt thereof. - Google Patents
Novel bicyclic compound or salt thereof.Info
- Publication number
- MX2013007938A MX2013007938A MX2013007938A MX2013007938A MX2013007938A MX 2013007938 A MX2013007938 A MX 2013007938A MX 2013007938 A MX2013007938 A MX 2013007938A MX 2013007938 A MX2013007938 A MX 2013007938A MX 2013007938 A MX2013007938 A MX 2013007938A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- represent
- salt
- optionally substituted
- hydrogen atom
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Abstract
Provided is a novel bicyclic compound which is capable of inhibiting HSP90 and has a carcinostatic effect. A compound represented by general formula (I) or a salt thereof. In general formula (I): at least one of X<sup>1</sup>, X<sup>2</sup>, X<sup>3</sup> and X<sup>4</sup> represents N or N-oxide and the remainders are the same or different and represent C-R<sup>2</sup>; one or two of Y<sup>1</sup>, Y<sup>2</sup>, Y<sup>3</sup> and Y<sup>4</sup> represent C-R<sup>4</sup> and the remainders are the same or different and represent CH or N; R<sup>1</sup> represents an optionally substituted monocyclic or bicyclic unsaturated heterocyclic group having 1-4 hetero atoms, said hetero atoms being selected from among N, S and O; R<sup>2</sup> represents a hydrogen atom, an optionally substituted C1-6 alkyl group, etc.; R<sup>3</sup> represents -CO-R<sup>5</sup>, etc.; R<sup>4</sup> represents a hydrogen atom, -N(R<sup>7</sup>)(R<sup>8</sup>), etc.; R<sup>5</sup> represents a hydroxyl group, an amino group, etc.; and R<sup>7</sup> and R<sup>8</sup> are the same or different and represent a hydrogen atom, an optionally substituted C1-6 alkyl group, etc.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011002104 | 2011-01-07 | ||
PCT/JP2012/050141 WO2012093708A1 (en) | 2011-01-07 | 2012-01-06 | Novel bicyclic compound or salt thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2013007938A true MX2013007938A (en) | 2013-11-01 |
Family
ID=46457558
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013007938A MX2013007938A (en) | 2011-01-07 | 2012-01-06 | Novel bicyclic compound or salt thereof. |
Country Status (14)
Country | Link |
---|---|
US (1) | US8912181B2 (en) |
EP (1) | EP2662357B1 (en) |
JP (1) | JP5792201B2 (en) |
KR (1) | KR20140025327A (en) |
CN (1) | CN103313970B (en) |
AU (1) | AU2012204651A1 (en) |
BR (1) | BR112013017520A2 (en) |
CA (1) | CA2824013A1 (en) |
ES (1) | ES2598830T3 (en) |
HK (1) | HK1185079A1 (en) |
MX (1) | MX2013007938A (en) |
RU (1) | RU2013136895A (en) |
TW (1) | TW201309668A (en) |
WO (1) | WO2012093708A1 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011004610A1 (en) | 2009-07-10 | 2011-01-13 | 大鵬薬品工業株式会社 | Azabicyclo compound and salt thereof |
HUE034807T2 (en) | 2013-08-22 | 2018-02-28 | Taiho Pharmaceutical Co Ltd | Novel quinoline-substituted compound |
US10100095B2 (en) | 2013-10-02 | 2018-10-16 | Taiho Pharmaceutical Co., Ltd. | Resistant mutant 90 kDa heat shock protein |
CN104744459A (en) * | 2013-12-27 | 2015-07-01 | 中国药科大学 | Synthetic method of pyridopyridone and derivatives thereof |
RU2697521C2 (en) * | 2015-05-12 | 2019-08-15 | Тайхо Фармасьютикал Ко., Лтд. | Azabicyclic compound crystals |
JOP20190073A1 (en) | 2016-10-31 | 2019-04-07 | Taiho Pharmaceutical Co Ltd | Selective inhibitor of exon 20 insertion mutant egfr |
JOP20200044A1 (en) | 2017-09-01 | 2020-02-26 | Taiho Pharmaceutical Co Ltd | Exon 18 and/or exon 21 mutant egfr selective inhibitor |
CN114685492A (en) * | 2020-12-31 | 2022-07-01 | 杭州领业医药科技有限公司 | TAS-116 crystal form, preparation method, pharmaceutical composition and application thereof |
CN117050010B (en) * | 2023-10-11 | 2024-01-05 | 湖南工程学院 | Synthesis method of 2,2' -biquinoline and derivatives thereof |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57203068A (en) * | 1981-06-08 | 1982-12-13 | Teikoku Hormone Mfg Co Ltd | Novel 1-phenylisoquinoline derivative |
AR028782A1 (en) * | 2000-07-05 | 2003-05-21 | Taisho Pharmaceutical Co Ltd | TETRAHYDROPIRIDINE OR PIPERIDINE HETEROCICLIC DERIVATIVES |
DE102005022977A1 (en) * | 2005-05-19 | 2006-12-07 | Merck Patent Gmbh | Phenylchinazolinderivate |
JP2009508872A (en) | 2005-09-16 | 2009-03-05 | セレネックス, インコーポレイテッド | Carbazole derivatives |
WO2008024978A2 (en) | 2006-08-24 | 2008-02-28 | Serenex, Inc. | Tetrahydroindolone and tetrahydroindazolone derivatives |
WO2008026704A1 (en) * | 2006-08-31 | 2008-03-06 | Kyowa Hakko Kogyo Co., Ltd. | Isoquinoline derivative |
JP5269086B2 (en) | 2007-11-15 | 2013-08-21 | ギリアード サイエンシス インコーポレーテッド | Human immunodeficiency virus replication inhibitor |
KR20100094554A (en) | 2007-12-06 | 2010-08-26 | 쉐링 코포레이션 | Gamma secretase modulators |
FR2928645A1 (en) * | 2008-03-14 | 2009-09-18 | Sanofi Aventis Sa | NOVEL CARBAZOLE DERIVATIVES INHIBITORS OF HSP90, COMPOSITIONS CONTAINING SAME AND USE THEREOF |
GB0807910D0 (en) * | 2008-04-30 | 2008-06-04 | Glaxo Group Ltd | Compounds |
WO2010042489A2 (en) | 2008-10-06 | 2010-04-15 | Emory University | Aminoquinoline derived heat shock protein 90 inhibitors, methods of preparing same, and methods for their use |
TW201038553A (en) | 2009-03-19 | 2010-11-01 | Sanofi Aventis | Novel indazole derivatives which inhibit HSP90, compositions containing them and use thereof |
WO2011004610A1 (en) | 2009-07-10 | 2011-01-13 | 大鵬薬品工業株式会社 | Azabicyclo compound and salt thereof |
-
2012
- 2012-01-06 MX MX2013007938A patent/MX2013007938A/en not_active Application Discontinuation
- 2012-01-06 TW TW101100719A patent/TW201309668A/en unknown
- 2012-01-06 WO PCT/JP2012/050141 patent/WO2012093708A1/en active Application Filing
- 2012-01-06 EP EP12732119.8A patent/EP2662357B1/en not_active Not-in-force
- 2012-01-06 JP JP2012551881A patent/JP5792201B2/en not_active Expired - Fee Related
- 2012-01-06 US US13/978,613 patent/US8912181B2/en not_active Expired - Fee Related
- 2012-01-06 ES ES12732119.8T patent/ES2598830T3/en active Active
- 2012-01-06 KR KR1020137017452A patent/KR20140025327A/en not_active Application Discontinuation
- 2012-01-06 BR BR112013017520A patent/BR112013017520A2/en not_active IP Right Cessation
- 2012-01-06 AU AU2012204651A patent/AU2012204651A1/en not_active Abandoned
- 2012-01-06 CA CA2824013A patent/CA2824013A1/en not_active Abandoned
- 2012-01-06 RU RU2013136895/04A patent/RU2013136895A/en not_active Application Discontinuation
- 2012-01-06 CN CN201280004872.4A patent/CN103313970B/en not_active Expired - Fee Related
-
2013
- 2013-11-11 HK HK13112605.7A patent/HK1185079A1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
WO2012093708A1 (en) | 2012-07-12 |
CN103313970A (en) | 2013-09-18 |
JP5792201B2 (en) | 2015-10-07 |
EP2662357B1 (en) | 2016-08-03 |
CA2824013A1 (en) | 2012-07-12 |
HK1185079A1 (en) | 2014-02-07 |
EP2662357A1 (en) | 2013-11-13 |
KR20140025327A (en) | 2014-03-04 |
US20130296320A1 (en) | 2013-11-07 |
AU2012204651A1 (en) | 2013-08-01 |
RU2013136895A (en) | 2015-02-20 |
US8912181B2 (en) | 2014-12-16 |
JPWO2012093708A1 (en) | 2014-06-09 |
EP2662357A4 (en) | 2014-07-30 |
BR112013017520A2 (en) | 2016-09-27 |
ES2598830T3 (en) | 2017-01-30 |
CN103313970B (en) | 2016-09-07 |
TW201309668A (en) | 2013-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2013007938A (en) | Novel bicyclic compound or salt thereof. | |
PH12016500169A1 (en) | Polymorph of syk inhibitors | |
CA2875877C (en) | Syk inhibitors | |
WO2014144545A3 (en) | Substituted benzoxazoles and methods of use thereof | |
MX2021014531A (en) | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith. | |
MY152972A (en) | Azabicyclo compound and salt thereof | |
RS53503B1 (en) | An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase | |
MX365776B (en) | Alkylphenylsulphide derivative and pest control agent. | |
MX2013012776A (en) | Amino-pyridine-containing spleen tyrosine kinase (syk) inhibitors. | |
EA201390884A1 (en) | AZABENZIMADAZLES AS ANTIVIRAL MEANS AGAINST RESPIRATORY SYNCYTIAL VIRUS | |
RS54048B1 (en) | Parasiticidal dihydroisoxazole compounds | |
IN2014CN03976A (en) | ||
UA105786C2 (en) | Amine addition salts containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as dhodh innhibitors | |
PH12015501226A1 (en) | Crystalline 6,7-unsaturated-7-carbamoyl morphinane derivative, and method for producing the same | |
TW201129564A (en) | Diphenylpyrazolopyridine derivatives, preparation thereof and therapeutic use thereof | |
MX2011011281A (en) | Carbinol compound having heterocyclic linker. | |
MX2016004963A (en) | Salt and crystal forms of plk-4 inhibitor. | |
NZ712660A (en) | Dicarboxylic acid compound | |
MX341341B (en) | Benzamide derivatives and their use as hsp90 inhibtors. | |
MX2013007296A (en) | Novel substituted isoquinoline derivative. | |
MX2013010554A (en) | Nitrogen-containing saturated heterocyclic compound. | |
UA111950C2 (en) | HETEROCYCLIC COMPOUNDS FOR TREATMENT OR PREVENTION OF DISORDERS CAUSED BY REDUCED NERROTRANSMISSION OF SEROTONIN, NOREPINEPHIN OR DOPIN | |
MX359399B (en) | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS. | |
RS53965B1 (en) | Acylbenzene derivative | |
TW201613933A (en) | Long acting HIV protease inhibitor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |